The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| JAGX | -92.37% | -100% | -87.49% | -100% |
| S&P | +18.13% | +110.72% | +16.08% | +178% |
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.98M | 9.5% |
| Gross Profit | $1.90M | 9.3% |
| Gross Margin | 63.65% | -0.1% |
| Market Cap | $3.34M | -79.5% |
| Market Cap / Employee | $0.07M | 0.0% |
| Employees | 49 | 0.0% |
| Net Income | -$10.56M | -9.7% |
| EBITDA | -$7.45M | -12.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.21M | -86.2% |
| Accounts Receivable | $1.17M | -9.7% |
| Inventory | 10.7 | 12.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $11.70M | -48.3% |
| Short Term Debt | $18.83M | 63.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -74.08% | -11.3% |
| Return On Invested Capital | -149.21% | 14.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.19M | 0.0% |
| Operating Free Cash Flow | -$6.19M | 24.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.03 | 1.83 | 0.35 | 0.95 | -29.91% |
| Price to Sales | 1.21 | 1.14 | 0.26 | 0.22 | -73.78% |
| Price to Tangible Book Value | -105.59 | -49.32 | -0.22 | -0.10 | -99.80% |
| Enterprise Value to EBITDA | -5.34 | -5.76 | -4.19 | -4.33 | 0.22% |
| Return on Equity | -432.4% | -522.6% | -423.8% | -296.9% | 4.17% |
| Total Debt | $34.27M | $36.53M | $38.34M | $30.53M | -10.62% |
JAGX earnings call for the period ending June 30, 2021.
JAGX earnings call for the period ending March 31, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
